Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials

Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing approximately 85% of cases. The diagnosis is often made in the middle and late stages, necessitating systemic treatment as the primary therapeutic option. Despite sorafenib being the established standard of care for adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jiahui, Li, Mengnan, Ren, Boxu, Cheng, Le, Wang, Xiaoxiao, Ma, Zhaowu, Yong, Wei Peng, Chen, Xiaoguang, Wang, Lingzhi, Goh, Boon Cher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501787/
https://www.ncbi.nlm.nih.gov/pubmed/37719852
http://dx.doi.org/10.3389/fphar.2023.1261575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501787/
https://www.ncbi.nlm.nih.gov/pubmed/37719852
http://dx.doi.org/10.3389/fphar.2023.1261575

Ejemplares similares